Anti-EHF Rabbit Polyclonal Antibody for WB and ELISA - Q9NZC4

Core Product Specifications and Parameters

Biological Background: EHF Function and Localization

• EHF (ETS homologous factor), also known as ESE-3 or ESE3, is an ETS-domain transcription factor that binds to the core DNA motif GGAA.
• It functions as a transcriptional activator or repressor, playing a role in epithelial cell differentiation and proliferation.
• EHF may repress a specific subset of ETS/AP-1-responsive genes and modulates the nuclear response to mitogen-activated protein kinase (MAPK) signaling cascades.
• The protein is involved in the upregulation of death receptor DR5 (TNFRSF10B) through binding to Ets sequences in its promoter, linking it to apoptotic pathways.
• EHF is thought to act as a tumor suppressor or anti-oncogene, contributing to both development and carcinogenesis.
• The protein localizes to the nucleus, consistent with its role as a transcription factor.
• EHF is exclusively expressed in epithelial-rich tissues such as salivary gland, mammary gland, prostate, and lung, with weak expression in kidney and colon; it is absent in most other tissues.
• UniProt annotations highlight alternative splicing, DNA-binding, and nuclear localization as key features.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the N-terminal region (aa 1–113) of human EHF, suggesting the antibody primarily recognizes this epitope.
• For western blot, a band at approximately 35 kDa is expected; consider using nuclear extracts for enrichment.
• Given cross-reactivity with mouse, validate specificity in mouse tissue if used for comparative studies.
• For ELISA, optimize coating antigen and antibody dilution empirically according to your assay conditions.
• Confirm expression patterns in epithelial cell lines or tissues based on known tissue specificity to ensure target detection.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and researchers with comprehensive access to IVD raw materials, including validated antibody pairs and optimized polyclonal antibodies for transcription factors like EHF. Our platform supports workflows from early-stage development to clinical application, offering reliable sourcing of antibodies, antigens, and ancillary reagents tailored to epithelial cancer and differentiation studies. For bulk or custom requirements, we facilitate efficient procurement and technical support.